DECHRA VETERINARY PRODUCTS SAS : revenue, balance sheet and financial ratios

DECHRA VETERINARY PRODUCTS SAS is a French company founded 21 years ago, specialized in the sector Commerce de gros (commerce interentreprises) de produits pharmaceutiques. Based in MONTIGNY-LE-BRETONNEUX (78180), this company of category PME shows in 2025 a revenue of 132.6 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-09

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - DECHRA VETERINARY PRODUCTS SAS (SIREN 481585644)
Indicator 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016
Revenue 132 579 188 € 59 708 036 € 52 041 120 € 46 961 079 € 42 645 708 € 34 551 559 € 31 694 637 € 36 495 921 € 36 384 307 € 29 712 423 €
Net income 3 956 480 € 1 702 760 € 1 185 089 € 1 019 726 € 907 185 € 704 326 € 542 941 € 490 677 € 429 291 € 375 063 €
EBITDA 8 536 962 € 3 748 506 € 3 232 059 € 3 454 916 € 2 790 375 € 2 944 140 € 1 871 632 € 1 845 070 € 1 562 640 € 1 327 702 €
Net margin 3.0% 2.9% 2.3% 2.2% 2.1% 2.0% 1.7% 1.3% 1.2% 1.3%

Revenue and income statement

In 2025, DECHRA VETERINARY PRODUCTS SAS achieves revenue of 132.6 M€. Over the period 2016-2025, the company shows strong growth with a CAGR (compound annual growth rate) of +18.1%. Vs 2024, growth of +122% (59.7 M€ -> 132.6 M€). After deducting consumption (97.4 M€), gross margin stands at 35.2 M€, i.e. a rate of 27%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 8.5 M€, representing 6.4% of revenue. The operating margin remains fragile, requiring cost vigilance. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 4.0 M€, i.e. 3.0% of revenue. This profit can be retained or distributed to shareholders.

Revenue (2025) ?
Revenue
Definition
Total amount of sales of goods and services made by the company.
Formula
Sales of goods + Sold production

132 579 188 €

Gross margin (2025) ?
Gross margin
Definition
Difference between revenue and cost of goods sold.
Formula
Revenue - Cost of goods consumed

35 221 420 €

EBITDA (2025) ?
Gross Operating Surplus (EBITDA)
Definition
Resources generated by current operations, before depreciation and financial expenses.
Formula
Value added - Personnel expenses - Taxes
Interpretation
Positive = profitable activity

8 536 962 €

EBIT (2025) ?
EBIT (Operating Income)
Definition
Operating income, including depreciation and provisions.
Formula
EBITDA - Depreciation and provisions + Reversals

8 493 460 €

Net income (2025) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

3 956 480 €

EBITDA margin (2025) ?
EBITDA margin
Definition
Measures the company's operating profitability.
Formula
(EBE / CA) x 100
Interpretation
> 10% : Good profitability
5-10% : Average
< 5% : Low

6.4%

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 0%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 8%. Low autonomy: the company heavily depends on external financing (banks, suppliers). Cash flow represents 3.0% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment.

Debt ratio (2025) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

0.0%

Financial autonomy (2025) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

8.365%

Cash flow / Revenue (2025) ?
Cash flow / Revenue
Definition
Self-financing capacity relative to revenue.
Formula
(CAF / CA) x 100
Interpretation
The higher the ratio, the more cash the company generates

3.017%

Repayment capacity (2025) ?
Repayment capacity
Definition
Number of years needed to repay debts with cash flow.
Formula
Financial debt / Cash flow
Interpretation
< 3 years : Excellent
3-5 years : Fair
> 5 years : Warning

0.0

Asset age ratio (2025) ?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Interpretation
< 50% : Recent assets
50-70% : Normal wear
> 70% : Aging assets

30.0%

Solvency indicators evolution
DECHRA VETERINARY PRODUCTS SAS

Sector positioning

Debt ratio
0.0 2025
2023
2024
2025
Q1: 0.0
Med: 3.67
Q3: 28.55
Excellent

In 2025, the debt ratio of DECHRA VETERINARY PRODUCT... (0.00) ranks in the bottom 25% of the sector, which is positive. This ratio measures the weight of debt relative to equity. A low ratio indicates a solid financial structure with little dependence on creditors.

Financial autonomy
8.37% 2025
2023
2024
2025
Q1: 26.28%
Med: 43.48%
Q3: 62.04%
Watch

In 2025, the financial autonomy of DECHRA VETERINARY PRODUCT... (8.4%) ranks in the bottom 25% of the sector. This ratio represents the share of equity in total financing. Low autonomy may limit investment capacity and increase vulnerability.

Repayment capacity
0.0 years 2025
2023
2024
2025
Q1: 0.0 years
Med: 0.0 years
Q3: 0.67 years
Excellent

In 2025, the repayment capacity of DECHRA VETERINARY PRODUCT... (0.00) ranks in the bottom 25% of the sector, which is positive. This ratio indicates the number of years needed to repay debt with cash flow. A short capacity reflects controlled debt and good cash generation.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 110.90. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 51.4x. Operating income very largely covers interest expenses: high safety margin.

Liquidity ratio (2025) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

110.9

Interest coverage (2025) ?
Interest coverage
Definition
Ability to cover interest charges with operating income.
Formula
EBIT / Interest expenses
Interpretation
> 3 : Comfortable
1.5-3 : Acceptable
< 1.5 : Risk

51.437

Liquidity indicators evolution
DECHRA VETERINARY PRODUCTS SAS

Sector positioning

Liquidity ratio
110.9 2025
2023
2024
2025
Q1: 147.44
Med: 215.05
Q3: 310.05
Watch

In 2025, the liquidity ratio of DECHRA VETERINARY PRODUCT... (110.90) ranks in the bottom 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio below 1 may signal potential cash flow tensions.

Interest coverage
51.44x 2025
2023
2024
2025
Q1: 0.0x
Med: 0.36x
Q3: 5.44x
Excellent

In 2025, the interest coverage of DECHRA VETERINARY PRODUCT... (51.4x) ranks in the top 25% of the sector. This ratio indicates how many times operating income covers interest expenses. High coverage means financial charges weigh little on profitability.

Working capital requirement (WCR) and payment terms

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 33 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 43 days. Favorable situation: supplier credit is longer than customer credit by 10 days. Overall, WCR represents 50 days of revenue, i.e. 18.3 M€ to permanently finance. Over 2016-2025, WCR increased by +894%, requiring additional financing.

Operating WCR (2025) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

18 281 344 €

Customer credit (2025) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

33 j

Supplier credit (2025) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

43 j

Inventory turnover (2025) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

0 j

WCR in days of revenue (2025) ?
WCR in days of revenue
Definition
Expresses working capital requirement in days of revenue.
Formula
(Operating WCR / Revenue) x 360
Interpretation
The fewer days, the better the working capital management

50 j

WCR and payment terms evolution
DECHRA VETERINARY PRODUCTS SAS

Positioning of DECHRA VETERINARY PRODUCTS SAS in its sector

Comparison with sector Commerce de gros (commerce interentreprises) de produits pharmaceutiques

Valuation estimate

Based on 124 transactions of similar company sales (all years), the value of DECHRA VETERINARY PRODUCTS SAS is estimated at 12 125 374 € (range 6 261 271€ - 38 967 470€). With an EBITDA of 8 536 962€, the sector multiple of 0.7x is applied. The price/revenue ratio is 0.21x (conservative valuation). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.

Estimated enterprise value 2025
124 transactions
6261k€ 12125k€ 38967k€
12 125 374 € Range: 6 261 271€ - 38 967 470€
NAF 5 all-time

Valuation detail by method

Ajustez les pondérations selon votre analyse

EBITDA Multiple 50%
8 536 962 € × 0.7x
Estimation 6 009 041 €
2 840 688€ - 21 870 716€
Revenue Multiple 30%
132 579 188 € × 0.21x
Estimation 28 235 973 €
15 311 699€ - 85 527 227€
Net Income Multiple 20%
3 956 480 € × 0.8x
Estimation 3 250 310 €
1 237 091€ - 11 869 721€

Valuation evolution

How is this estimate calculated?

This estimate is based on the analysis of 124 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Commerce de gros (commerce interentreprises) de produits pharmaceutiques)

Compare DECHRA VETERINARY PRODUCTS SAS with other companies in the same sector:

Voir toutes les statistiques du secteur Commerce de gros (commerce interentreprises) de produits pharmaceutiques

Frequently asked questions about DECHRA VETERINARY PRODUCTS SAS

What is the revenue of DECHRA VETERINARY PRODUCTS SAS ?

The revenue of DECHRA VETERINARY PRODUCTS SAS in 2025 is 132.6 M€.

Is DECHRA VETERINARY PRODUCTS SAS profitable?

Yes, DECHRA VETERINARY PRODUCTS SAS generated a net profit of 4.0 M€ in 2025.

Where is the headquarters of DECHRA VETERINARY PRODUCTS SAS ?

The headquarters of DECHRA VETERINARY PRODUCTS SAS is located in MONTIGNY-LE-BRETONNEUX (78180), in the department Yvelines.

Where to find the tax return of DECHRA VETERINARY PRODUCTS SAS ?

The tax return of DECHRA VETERINARY PRODUCTS SAS is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does DECHRA VETERINARY PRODUCTS SAS operate?

DECHRA VETERINARY PRODUCTS SAS operates in the sector Commerce de gros (commerce interentreprises) de produits pharmaceutiques (NAF code 46.46Z). See the 'Sector positioning' section above to compare the company with its competitors.